The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care.
We have marketed the first SARS-CoV-2 rapid diagnostic kits including the world’s first genetic diagnostic test for the detection of SARS-CoV-2 directly from a saliva sample.

News

2021.08.25

Genomtec has filed a patent application for a set of primers for detecting Salmonella enterica infections, one of the most common infectious diseases among humans and animals

Company has filed a patent application for a proprietary primer set, diagnostic method and reaction mixture composition for genetic diagnosis of Salmonella enterica infections using the LAMP technique. The application was filed with the Patent Office of the Republic of Poland. The detection technology developed by Genomtec is faster and less expensive than those currently […]

2021.08.16

Genomtec intends to move to the Main Market of the Warsaw Stock Exchange (WSE)

Genomtec S.A. has expressed its intention to seek a transfer of the Company’s listing from the alternative stock exchange of NewConnect to the main market of the Warsaw Stock Exchange (WSE). Accordingly, the Board of Directors has convened an Extraordinary General Meeting for September 13 this year, for Genomtec shareholders to pass a resolution authorizing […]

2021.08.12

Genomtec’s flagship solution enters critical development phase. Company summarizes second quarter activities

Genomtec S.A. has published a report for the second quarter of 2021 containing financial results and a summary of the most important activities during this period, including a description of the progress of the Company’s flagship solution, which is a rapid mobile diagnostic platform – Genomtec ID. During the second quarter, the Company adapted the […]

Awards